ABSTRACT
INTRODUCTION
The adult heart can adapt to environmental stress by hypertrophy and vascular growth/remodeling 1 . Physiological or adaptive responses, as in the case of the exercised trained athletic heart, are characterized by balanced changes in both the cardiomyocytes and the vasculature. Negative consequences arise when these responses are not coordinated, as in the case of prolonged hypertension, and can lead to heart failure, arrhythmia, and death. The physiological and pathological responses overlap in some respects, especially in the early stages of adaptation. However, there are distinct characteristics to the physiological and pathological responses that have been delineated in humans and rodents 1 . These differences lie in the degree of vascularization of the myocardium, functional parameters, gene and protein expression, and the response to ischemic stress. An important goal in preventing heart disease is to understand how to induce physiological responses and suppress pathological responses.
We and others found that HEXIM1 is a tumor suppressor and cyclin-dependent kinase inhibitor, and that these functions are dependent on its C-terminal region 2 . We provided evidence that the HEXIM1 C-terminal region is critical for cardiovascular development. HEXIM1 protein was detected in the heart during cardiac growth and chamber maturation 3 . We created mice carrying an insertional mutation in the HEXIM1 gene that disrupted its C-terminal region and resulted in prenatal lethality. Heart defects in HEXIM1 mice included abnormal coronary patterning, reduction of coronary vascularization within the myocardium and thin ventricular walls. The expression of Vascular Endothelial Growth Factor-A (VEGF), known to affect angioblast invasion and myocardial proliferation and survival, was decreased in HEXIM1 mice compared to control littermates. These results suggest that HEXIM1 is critical for coronary vessel development and myocardial growth. Here we report that HEXIM1 induction in adult Accepted Manuscript at Case Western Reserve University on April 22, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from cardiomyocytes results in morphology, physiology, and gene expression that resembles those of a physiological rather than a pathological response of the heart. . pTET-HEXIM1 mice were generated as previously Treadmill. This test was modified from a previously protocol described 6 . Details are provided in the Supplementary Methods.
MATERIALS AND METHODS

Generation
MRI.
In vivo MRI experiments were performed on a 9.4T Bruker system equipped with a gradient insert and a volume receiver coil as previously published 7 . Animals were anesthetized via inhalation anesthesia with 1.5% isoflurane and monitored by evaluation of toe pinch reflex and breathing rate. Other details are in the Supplementary Methods. Telemetry. In preparation for implantation of transmitters, mice were anesthesized with an intraperitoneal injection of ketamine (50 mg/kg) and xylazine (10 mg/kg) and monitored by evaluation of toe pinch reflex and breathing rate. We used a radiotelemetry system (ETA-F10, Data Sciences International, St. Paul, MN) to monitor heart rate in conscious, unrestrained mice, as described previously 9 . Details are in the Supplementary Methods.
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Immunostaining. Frozen adult mouse hearts were processed for immunohistology and stained as previously described 3 . Details are in the Supplementary Methods.
Quantitation of immunostaining results.
Immunostaining results were analyzed using a modified protocol 10 . Details are in the Supplementary Methods.
Cell culture and transfections. H9C2 cells [originally derived from embryonic rat heart tissue 11 ) were maintained and transfected as previously described 3 . Details are in the Supplementary Methods.
Northern blot analyses. Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) and analyzed using Northern blotting as previously described 12 .
Accepted Manuscript Western blot analyses. Western blot experiments were performed as previously described 13 .
Details are in the Supplementary Methods.
RESULTS
Consequences of cardiomyocyte-specific expression of HEXIM1 to the phenotype of the adult heart. HEXIM1 is expressed in embryonic and fetal hearts, with decreased expression in adult hearts (Fig. 1A) . Because of the critical roles of HEXIM1 in coronary vessel development and myocardial growth in the developing heart we investigated whether HEXIM1 re-expression would have beneficial effects on cardiovascular function in the adult heart. A tetracyclineresponsive binary α-Mhc transgene system described in the Methods section was used to allow temporally regulated expression of HEXIM1 in cardiomyocytes. HEXIM1 expression was induced by Doxycycline (Dox) in the hearts of Mhc-HEXIM1 mice as early as 7 days after the start of Dox treatment to a level observed in fetal mice (Fig. 1A) . HEXIM1 immunostaining showed little or no staining in the heart sections of the untreated mice but distinct nuclear staining was evident in the cardiomyocytes of the Dox-treated mice ( Supplementary Fig. 1A ).
The induction of HEXIM1 is heart specific ( Supplementary Fig. 1B ) and Dox dose dependent ( Supplementary Fig. 1C ).
Heart sections stained with Masson's trichrome, Oil Red O, or TUNEL revealed no obvious qualitative differences in staining patterns between Dox-treated and untreated mice indicating HEXIM1 induction did not promote fibrosis, deposition of fat, nor apoptosis, respectively ( Supplementary Fig. 2 ). Dox-treated mice had heavier hearts, higher heart weight to body weight ratios (Fig. 1B) , and larger hearts (Fig. 1C) . Dox treatment of Mhc-rtTA mice did not induce a change in heart weight to body weight ratios ( Supplementary Fig. 3A ). The effects of HEXIM1 re-expression were reversible; the hearts returned to normal weight and size after 40
Accepted Manuscript Cardiac performance assayed by in vivo MRI, echocardiography, and endurance testing by treadmill. We examined heart function by subjecting Mhc-HEXIM1 mice (± Dox treatment)
to in vivo cardiac Magnetic Resonance Imaging (MRI) and echocardiography. Data from anesthetized mice revealed significantly lower heart rates in Dox-treated Mhc-HEXIM1 mice compared to controls (Fig. 3A) . Dox treatment of Mhc-rtTA mice did not induce changes in heart rates ( Supplementary Fig. 3B ). In addition significantly higher ejection fractions were documented in Dox-treated Mhc-HEXIM1 mice (Fig. 3B) . Analysis of the ventricular volume at three levels showed a tendency toward being larger in Dox-treated Mhc-HEXIM1 mice, consistent with the higher heart/body weight ratio (36% higher than the control) and histological analysis. The MRI data also indicated that the time to peak radial and circumferential strains Fig. 6 ). Heart rate and time to peak strain of the two background control animals with no transgene (FVB and SV/129) and the untreated Mhc-HEXIM1 mice were not different from each other. We also tested reversibility of the effects of HEXIM1 reexpression.
After 40 days of Dox withdrawal HR returned to levels not statistically different from untreated Mhc-HEXIM1 mice (Fig. 3D ).
Echocardiography data revealed that posterior wall thickness (PWT) was significantly greater in Dox-treated Mhc-HEXIM1 mice consistent with the increase in heart/body weight ratio (Supplementary Table II) . Given the significant decrease in HR with no significant compensatory increase in stroke volume, cardiac index (CI) was significantly lower in the long axis view of the Dox-treated Mhc-HEXIM1 group. There were no significant differences in other baseline structural or functional echocardiographic parameters between the treatment and control HEXIM1 groups. The increase in ejection fraction detected using MRI, did not reach significance based on echocardiographic data. However, MRI analyses have been demonstrated to be more accurate and reproducible compared to 2D echocardiography and has increased sensitivity in detecting LV mass changes 14 . The functional responses (e.g. HR, cardiac index, ejection fraction, fractional shortening) to dobutamine stress were not different between Dox-treated and untreated Mhc-HEXIM1 groups, suggesting that HEXIM1 reexpression did not alter the adrenergic response (Supplementary Table III) . Because restraint and anesthesia can have an artifactual influence on physiological parameters we used radiotelemetry to measure heart rates of conscious, untethered animals.
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Consistent with MRI and echocardiography data, the heart rate of Dox-treated Mhc-HEXIM1 mice was lower than that of control mice (Fig. 4A) . In addition ECG recordings from telemetry data revealed that Dox-treated Mhc-HEXIM1 mice had prolongation of the Q-Tc interval compared to control mice (Fig. 4B) . No sustained arrhythmias were noted during the 6 hours of continuous recordings. While prolongation of the Q-T interval does not necessarily indicate a susceptibility to arrhythmias and sudden death 15 , it will be important to investigate any changes in the inducibility of arrhythmias and other electrophysiological parameters in these mice.
We examined endurance exercise capacity of control and Dox-treated Mhc-HEXIM1 mice using a run to exhaustion treadmill test without prior training. Time to exhaustion was significantly longer in the Mhc-HEXIM1 mice compared to controls (Fig. 4C ).
HEXIM1 upregulation of pro-angiogenic and growth regulatory factors. We examined the molecular basis for the phenotypic and functional changes in Mhc-HEXIM1 mice. As expected from our studies in the developing heart expressing mutant HEXIM1
FGF9 expression was also increased with increased HEXIM1 expression (Fig. 5A ).
FGF9 promotes myocardial vascularization and hypertrophy in adult hearts 16 and likely contributes to the phenotype of Dox-treated Mhc-HEXIM1 mice. . We observed that HEXIM1 interacts with HIF-1α in H9C2 cardiomyocytes using endogenous co-immunoprecipitation experiments (Fig. 5B) . We also observed increased HIF-1α
Mechanism of regulation of HIF-1α
protein, but not mRNA levels after induction of HEXIM1 expression ( translocation to the nucleus and activation of its target genes (reviewed in ref. 21 ) Induction of calcineurin activity during pathological hypertrophy is associated with an increase in calcineurin protein 22 . HEXIM1 reexpression was not associated with changes in CaN expression (Fig. 6A) .
We also analyzed expression levels of metabolic control genes associated with physiological and pathological hypertrophy 23 by Western blot analyses. Relative to control hearts, Dox-treated Mhc-HEXIM1 mice exhibited decreased expression of GLUT4 that is associated with pathological hypertrophy and increased expression of PPARα (Fig. 6A) , a critical regulator of fatty acid oxidation that is associated with physiological hypertrophy. c-Myc expression was also increased in Dox-treated Mhc-HEXIM1 mice (Fig. 6A ). c-Myc regulated metabolic processes associated with preserved cardiac function and improved recovery from 
DISCUSSION
The significance of our studies is that the transcription factor HEXIM1 may be a regulator that encourages an adaptive rather than a pathological response to cardiac stress. We uncovered novel molecular mechanisms of HEXIM1 action in the control of cardiac vasculogenesis and, potentially, metabolism. First, HEXIM1 upregulates HIF-1α expression, the hypoxia-sensitive component of HIF-1 that is known to regulate a host of genes including those involved in angiogenesis and metabolism 28 . Second, HEXIM1 upregulates another key transcription factor GATA4 that is known to regulate growth regulatory and angiogenic genes compensatory hypertrophy in cardiomyocytes is supported by a report that HEXIM1 expression is decreased in a calcineurin model of cardiac hypertrophy, which coincides with an increase in P-TEFb activity 34 . Conversely, increased expression of the full-length HEXIM1 would be expected to inhibit P-TEFb activity. Thus some of the beneficial effects of HEXIM1 in cardiac function may be due to its ability to inhibit P-TEFb. A recent report on the prevention of right ventricular hypertrophy in hypoxia induced pulmonary hypertension by cardiomyocyte specific expression of HEXIM1 can also be attributed to HEXIM1 inhibition of P-TEFb activity 35 . It should be noted however that HEXIM1 overexpression in cardiomyocytes in that model was initiated during the embryonic stage and some of the effects on the adult heart in this model can be attributed to remodeling in the developing heart that can have effects on the function of the adult heart.
HEXIM1 regulation of VEGF gene transcription and vascularization is independent of its ability to inhibit the activity of the transcription elongation factor, P-TEFb
3
. Also, HEXIM1
regulation of HIF-1α appears to be direct, through an interaction that may regulate the stability of HIF-1α. HIF-1α-mediated cardioprotection has been observed in cardiac-specific HIF-1α transgenic mice after myocardial infarction 36 . The cause of cardioprotection likely involves many factors due to the activation of several HIF-1 target genes and the subsequent modulation of pathways involved in β-catenin signaling 37 , the purinergic signaling pathways 38 , glucose metabolism 37 , and lipid metabolism 39 .
Under some conditions such as during exercise and in certain pathologic states such as hypertrophy, the heart becomes increasingly dependent upon glucose to meet its metabolic demands 40 . Changes in GLUT transporters are an initial response to the hypertrophic stimulus 41 . High glucose conditions stimulate the production of angiotensin II (Ang II), a known A striking finding was that the HEXIM1 reexpression in adult cardiomyocytes resulted in bradycardia without compromise of other cardiomechanical parameters. One explanation for the bradycardia is that, as in physiological hypertrophy in humans 44 , the low resting heart rates are due to higher vagal tone as a result of more efficient cardiac function in the Dox-treated mice.
Another possibility is that increased HEXIM1 expression in sinus node cardiomyocytes alters intrinsic pacemaker function of these cells. Prolonged QT as we have found in the Mhc-HEXIM1 mice has also been reported for physiological hypertrophy in human (reviewed in ref. 45 ) and suggested to be due to electrophysiological remodeling. These possibilities are currently being tested.
It has been previously reported that bradycardia induced by administration of ivabradine or beta-blockers resulted in increased angiogenesis within the myocardium and increased cardiomyocyte survival after infarction in rodent models 46 . The clinical use of heart rate reduction therapy (HRR) by pharmacological intervention reduces morbidity and mortality due to coronary artery disease and other cardiac pathologies 47 . However the effect of reducing HR on the myocardial vasculature in these clinical studies is not known. 
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